Collegium Pharmaceutical (COLL) to Release Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) will likely be announcing its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $1.54 per share and revenue of $179.68 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Collegium Pharmaceutical Price Performance

COLL stock opened at $29.19 on Tuesday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical has a 52 week low of $28.39 and a 52 week high of $42.29. The firm’s fifty day moving average is $30.95 and its 200 day moving average is $33.63. The firm has a market cap of $941.38 million, a P/E ratio of 12.58 and a beta of 0.82.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now directly owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on COLL shares. Piper Sandler reduced their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.